Seminars in Arthritis and Rheumatism · Oct 22, 2026
Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis
By Gumber L, Scholfield S, Miller CA et al.
INTRODUCTION: Rheumatic immune-mediated inflammatory diseases (IMIDs) are associated with increased cardiovascular morbidity and mortality. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) improve cardiometabolic outcomes in high-risk populations, but IMID patients were largely excluded from major trials. It remains unclear to what extent these benefits extend to IMIDs. METHODS: Following PRISMA guidance, MEDLINE, Embase, PubMed, Cochrane Library and Web of Science Core Collection databases were searched (PROSPERO: CRD420261289071). Observational and interventional adult IMID studies reporting all cause-mortality, major adverse cardiovascular events (MACE; cardiovascular mortality, myocardial infarction, stroke, heart failure), safety or IMID disease activity with SGLT2i were included. RESULTS: Five studies including 11,190 IMID participants were identified: systemic sclerosis (SSc; 25.4%), systemic lupus erythematosus (SLE; 70.9%) and other IMIDs (3.9%). Across three studies reporting MACE, SGLT2i use was associated with lower all-cause mortality and heart failure risk, with no clear effect on myocardial infarction. Safety data were variably reported, with infections, particularly genitourinary infections, were most frequently reported. Evidence on hospitalisation, treatment discontinuation and IMID flare was limited and inconsistent. CONCLUSION: Predominantly observational data suggest a potential cardiovascular benefit of SGLT2 inhibitors in rheumatic IMIDs, but the available evidence is confined largely to SLE and SSc populations. Whilst SGLT2 inhibitors should be used in established indications of type 2 diabetes mellitus, heart failure and chronic kidney disease, prospective and controlled studies in IMID populations are needed to establish their cardiovascular benefit, clarify safety and evaluate for effect on disease activity.
doi.org/10.1016/j.semarthrit.2026.153090Open accessPubMed 42962450Interventions